These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34027694)

  • 21. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
    Peláez-García A; Yébenes L; Berjón A; Angulo A; Zamora P; Sánchez-Méndez JI; Espinosa E; Redondo A; Heredia-Soto V; Mendiola M; Feliú J; Hardisson D
    PLoS One; 2017; 12(9):e0183452. PubMed ID: 28886093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
    Dinh P; Graham JD; Elder EN; Kabir M; Doan TB; French J; Meybodi F; Hui R; Wilcken NR; Harnett PR; Hsu J; Stuart KE; Wang T; Ahern V; Brennan M; Fox SB; Dear RF; Lim E; White M; Mann GB; Pathmanathan N
    Breast Cancer Res Treat; 2022 Feb; 191(3):501-511. PubMed ID: 34853987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
    Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
    Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of EndoPredict
    Thangarajah F; Eichler C; Fromme J; Malter W; Caroline Radosa J; Ludwig S; Puppe J; Paepke S; Warm M
    Arch Gynecol Obstet; 2019 May; 299(5):1437-1442. PubMed ID: 30783737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer.
    Jung W; Kim K; Moon BI
    Breast Care (Basel); 2022 Dec; 17(6):561-566. PubMed ID: 36590151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
    Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
    Jakubowicz E; Martin B; Hoffmann R; Kröncke T; Jung T; Steierl R; Steinfeld D; Schenkirsch G; Kriegsmann J; Märkl B
    Breast J; 2019 May; 25(3):450-454. PubMed ID: 31001905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint.
    Amezcua-Gálvez JE; Lopez-Garcia CA; Villarreal-Garza C; Lopez-Rivera V; Canavati-Marcos M; Santuario-Facio S; Dono A; Monroig-Bosque PDC; Ortiz-López R; Leal-Lopez A; Sofía Gómez-Macías G
    Mol Clin Oncol; 2022 Sep; 17(3):132. PubMed ID: 35949891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
    Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
    Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
    JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Lehmann-Che J; Miquel C; Wong J; Callens C; Rouleau E; Quillien V; Lozano N; Cayre A; Lacroix L; Bieche I; Bertheau P; Teixeira L; Penault-Llorca F; Lamy PJ; DE Cremoux P;
    Anticancer Res; 2018 May; 38(5):2909-2914. PubMed ID: 29715116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
    Jahn SW; Bösl A; Tsybrovskyy O; Gruber-Rossipal C; Helfgott R; Fitzal F; Knauer M; Balic M; Jasarevic Z; Offner F; Moinfar F
    Br J Cancer; 2020 Jun; 122(12):1744-1746. PubMed ID: 32336753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.
    Vieira SC; Dos Reis CA; Holanda MEF; da Silva Fontinele DR; Leal AIC; de Lima FT
    Breast Dis; 2024; 43(1):237-242. PubMed ID: 38995764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
    Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
    Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
    Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
    Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
    Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
    Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
    Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
    Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.